

Provider alert

Blue Cross commercial and BCN commercial Categories: Authorizations/referrals, Pharmacy Date posted: Aug. 22, 2023

Requirements for prior authorization of Omisirge

Omisirge[®] is a new-to-market cellular therapy that was recently approved by the Blue Cross Blue Shield of Michigan and Blue Care Network Pharmacy and Therapeutics committee.

On May 23, 2023, we published a <u>provider alert</u> stating that Omisirge will require prior authorization for most commercial members for dates of service on or after June 8, 2023.

Important: The member must have an approval for a stem cell transplant on file through the Blue Cross and BCN Human Organ Transplant Program before a prior authorization request for Omisirge can be approved.

You can view the complete requirements in our Omisirge medical policy. To access the medical policy:

- 1. Go to bcbsm.com/providers.
- 2. Click Resources.
- 3. Click Search Medical Policies.
- 4. In the <u>Medical Policy Router Search</u> page, enter *Omisirge* in the Policy/Topic Keyword field and press *Enter*.
- 5. Click the link to open the Omisirge medical policy.